MedTrace Logo

Macrolide Mediates Pulmonary Infection of Pseudomonas Aeruginosa

NCT02491723 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2016-10-14

No results posted yet for this study

Summary

It is acknowledged that IL-18, as a product of the inflammasome, is involved in host defence against viral and bacterial stimuli by modulating the immune response. The aim of this study was to determine IL-18 levels in serum of patients with Bronchiectasis and to investigate whether macrolide attenuate its levels.

Conditions

Interventions

DRUG

Azithromycin

Patients with bronchiectasis treated with Azithromycin for three to five days.

Sponsors & Collaborators

  • Jin-Fu Xu

    lead OTHER

Principal Investigators

  • Jin-Fu Xu, PhD · Shanghai Pulmonary Hospital, Shanghai, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02491723 on ClinicalTrials.gov